Latest News

Global Leader
in Stem Cell Therapeutics

0+
Number of registered patents in Korea and overseas
0+
Number of national R&D grants received in Korea
0
Number of private cord blood units stored
0%
Percentage of R&D staff

1st Generation Cord Blood-derived Stem Cell Products

CARTISTEM®

Treatment of knee cartilage defects including for patients with Knee Osteoarthritis

CARTISTEM® – allogeneic umbilical cord blood-derived mesenchymal stem cells, is used for the treatment of knee cartilage defects in patients with Osteoarthritis (with ICRS grade* IV cartilage defect) caused by degeneration or repetitive trauma.

PNEUMOSTEM®

Preventive treatment of bronchopulmonary dysplasia(BPD)

PNEUMOSTEM® an allogeneic umbilical cord blood-derived mesenchymal stem cell product, is currently under development for the preventive treatment of Bronchopulmonary Dysplasia(BPD) in premature infants. Currently, Phase 2 clinical trial is ongoing in Korea and PNEUMOSTEM® has been Orphan Drug designated by US FDA and EMA. Recently, US FDA granted a Fast Track Designation for PNEUMOSTEM®.

NEUROSTEM®

Treatment of Alzheimer’s Disease

NEUROSTEM® an allogeneic umbilical cord blood-derived mesenchymal stem cell product, is under development for the treatment of Alzheimer’s Disease. Currently, NEUROSTEM® is undergoing Phase 2a clinical trial after successfully completing the Phase 1 clinical trial in Korea.

2nd Generation Cord Blood-derived Stem Cell Products

SMUP-IA-01

Intra-articular Injectable treatment for osteoarthritis

SMUP-IA-01, SMUP allogeneic umbilical cord blood-derived mesenchymal stem cells, is currently under development for the treatment and prevention of Osteoarthritis. Currently, SMUP-IA-01 is undergoing Phase 1 clinical trial in Korea with IND from the MFDS.

SMUP-IV-01

Intra-venous infusion treatment for diabetic nephropathy

SMUP-IV-01, an SMUP allogeneic umbilical cord blood-derived mesenchymal stem cels, is under development for the treatment and prevention of Diabetic Nephropathy. Currently, SMUP-IV-01 is in the process of applying for phase 1 clinical trial of the MFDS.

Global Leader in Stem Cell Therapeutics

As a global leader in biotechnology with cutting-edge Technologies in Stem Cell Therapeutics, MEDIPOST continues to innovate and challenge to tackle unmet medical needs.

Menu